Skip to content
OpenCapital
Get started

ANI Pharmaceuticals ANIP Q2 2025 earnings

Reported August 8, 2025 · Before market open

Revenue$211.4MBeat by $2.6M
EPS$1.80Beat by $0.42
Revenue estimate$208.8M
EPS estimate$1.38

Next report

Aug 7, 2026 (In 1 week)
Revenue estimate$260.1M
EPS estimate$2.01

Financials

Q2 2025

Income statement

See full
Revenue$211.4M+53.1%
Gross profit$136.8M+70.2%
Operating income$13.9M+169%
Net income$8.5M+474%
EPS (diluted)$0.36+357%

Balance sheet

See full
Cash & equivalents$217.8M-9.3%
Total debt$314.7M+10.3%
Total equity$436.8M-4.2%
Total assets$1.3B+45.9%

Cash flow

See full
Operating cash flow$75.8M+335%
CapEx$4.0M-9.8%
Free cash flow$71.8M+454%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.45B+8.6%
Enterprise value$1.55B+12.1%
P/S1.9×-0.5×

Profitability

See full
Gross margin61.1%-0.3pp
Net margin-1.4%-6.4pp
FCF margin16.8%-1.7pp

Returns & leverage

See full
Return on equity-2.3%-8.5pp
Debt / equity0.7×+0.1×
Current ratio2.5×-1.4×

Versus estimates

Revenue

Q1 2026$237.5MBeat by $29.8MQ4 2025$247.1MBeat by $16.0MQ3 2025$227.8MMiss by $4.4M
Q2 2025$211.4MBeat by $2.6M
Q1 2025$197.1MBeat by $8.4MQ4 2024$190.6MBeat by $20.6M

Diluted EPS

Q1 2026$2.05Beat by $0.77Q4 2025$2.33Beat by $0.34Q3 2025$2.04Beat by $0.30
Q2 2025$1.80Beat by $0.42
Q1 2025$1.70Beat by $0.33Q4 2024$1.63Beat by $0.22

Ask the moment ANI Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did ANI Pharmaceuticals report Q2 2025 earnings?
ANI Pharmaceuticals (ANIP) reported Q2 2025 earnings on August 8, 2025 before market open.
What were ANI Pharmaceuticals's Q2 2025 revenue and EPS?
ANI Pharmaceuticals reported revenue of $211.4M and eps of $1.80 for Q2 2025.
Did ANI Pharmaceuticals beat estimates in Q2 2025?
Revenue beat the consensus estimate of $208.8M by $2.6M. EPS beat the consensus estimate of $1.38 by $0.42.
How did ANI Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 53.1% from $138.0M a year earlier and eps grew 76.5% from $1.02.
Where can I find ANI Pharmaceuticals's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001023024-25-000082) directly on SEC EDGAR. The filing index links above go to sec.gov.